Getting closer to prostate cancer in patients - what scientists should want from clinicians

Abstract

For scientists pursuing drug development for prostate cancer, it is critical that an appropriate ex vivo or in vitro model system is available for study. Cancer research has generally consisted of: (1) finding the means to arrest fast growing cancer cells; or (2) (as a compromise) to slow down the excessive rate of cell growth; or in the best case (3) to kill the cancer cells whilst sparing the surrounding normal tissues. As the knowledge of the biological nature of the cancer cell improves, it has become increasingly apparent that such a simplistic attitude to cancer therapy development or indeed diagnosis is rapidly outdated, and a closer liaison between the clinic and the laboratory studies is more important than ever as the author seeks to target specific gene expression pathways, specific signaling pathways, cancer specific mutations and indeed the interactions between cancer cells and their micro-environment, all of which provide a tremendous potential for novel therapeutic development.

Keywords

Prostate cancer treatments / model systems / primary cultures / pre-clinical studies

References

[1] Chen W,Haiech J,Zeniou M.Cancer stem cell quiescence and plasticity as major challenges in cancer therapy..Stem Cells Int2016;2016:1740936 PMCID:PMC4932171

[2] Frame FM,Collins AT,Mann VM,Meuth M,Maitland NJ.HDAC inhibitor confers radiosensitivity to prostate stem-like cells..Br J Cancer2013;109:3023-33 PMCID:PMC3859953

[3] MacRae EJ,Ryan R,Hamdy FC,Lewis CE.Gene therapy for prostate cancer: current strategies and new cell-based approaches..Prostate2006;66:470-94

[4] Gleason DF.Classification of prostatic carcinomas..Cancer Chemother Rep1966;50:125-8

[5] Epstein JI.An update of the Gleason grading system..J Urol2010;183:433-40

[6] Epstein JI,Amin MB,ISUP Grading Committee..The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma..Am J Surg Pathol2005;29:1228-42

[7] Gleason DF.Histologic grading of prostate cancer: a perspective..Hum Pathol1992;23:273-9

[8] Gundem G,Kremeyer B,Tubio JM,Brewer DS,Hognas G,Kivinummi K,Latimer C,Dawson KJ,Emmert-Buck MR,Foster C,Easton D,ICGC Prostate Group,Cooper CS,Visakorpi T,McDermott U,Bova GS.The evolutionary history of lethal metastatic prostate cancer..Nature2015;520:353-7 PMCID:PMC4413032

[9] Huang J,Sun Y.Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy..Curr Opin Urol2013;23:189-93 PMCID:PMC4086526

[10] Friedlander TW,Tomlins SA,Kobayashi Y,Rubin MA,Chinnaiyan A,Ryan CJ.Common structural and epigenetic changes in the genome of castration-resistant prostate cancer..Cancer Res2012;72:616-25

[11] Wyatt AW.Targeting the adaptive molecular landscape of castration-resistant prostate cancer..EMBO Mol Med2015;7:878-94 PMCID:PMC4520654

[12] Lohr JG,Cibulskis K,Rosenberg M,Francis JM,Shalek AK,Trombetta JJ,Tallapragada N,Kim S,Sougnez C,Wong B,Van Allen EM,Lis RT,Li T,Ly A,Clancy TE,Regev A,Hahn WC,Golub TR,Boehm JS.Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer..Nat Biotechnol2014;32:479-84 PMCID:PMC4034575

[13] Beltran H,Park K,Sboner A,Wang Y,Terry S,Dhir R,de la Taille A,Gerstein MB,Pienta KJ,Wang Y,Gleave ME,Nanus DM.Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets..Cancer Discov2011;1:487-95 PMCID:PMC3290518

[14] Beltran H,Mosquera JM,Puca L,Marotz C,Chakravarthi BV,Tomlins SA,Tagawa ST,Elemento O,Garraway LA,Demichelis F.Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer..Nat Med2016;22:298-305 PMCID:PMC4777652

[15] Horoszewicz JS,Chu TM,Friedman M,Kim U,Kakati S,Sandberg AA.The LNCaP cell line -- a new model for studies on human prostatic carcinoma..Prog Clin Biol Res1980;37:115-32

[16] Tran C,Clegg NJ,Watson PA,Wongvipat J,Yoo D,Wasielewska T,Chen CD,Beer TM,Scher HI,Sawyers CL.Development of a second-generation antiandrogen for treatment of advanced prostate cancer..Science2009;324:787-90 PMCID:PMC2981508

[17] Saad F.Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer..Ther Adv Urol2013;5:201-10 PMCID:PMC3721441

[18] Merseburger AS,von Klot CA.An update on enzalutamide in the treatment of prostate cancer..Ther Adv Urol2015;7:9-21 PMCID:PMC4294802

[19] Cicero G,Dorangricchia P.The clinical efficacy of enzalutamide in metastatic prostate cancer: prospective single-center study..Anticancer Res2017;37:1475-80

[20] Scher HI,Higano CS,Taplin ME,Rathkopf D,Yu EY,Hung D,Seely L,Danila DC,Larson S,Sawyers CL.Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study..Lancet2010;375:1437-46

[21] Higano CS,Taplin ME,Hirmand M,Scher HI.Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer..Eur Urol2015;68:795-801 PMCID:PMC5013546

[22] Butler DE,Walker HF,Mann VM,Davies BR,Maitland NJ.Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer..Oncotarget2017;8:56698-713

[23] Ulukaya E,Cevatemre B,Walker H,Simms MS,Yilmaz VT.Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells..PLoS One2013;8:e64278 PMCID:PMC3651166

[24] Rane JK,Maitland NJ.A detailed analysis of gene expression in human basal, luminal, and stromal cell populations from benign prostatic hyperplasia tissues and comparisons with cultured basal cells..Eur Urol2017;72:157-9

[25] Berthon P,Hopwood L,Maitland N.Functional expression of sv40 in normal human prostatic epithelial and fibroblastic cells - differentiation pattern of nontumorigenic cell-lines..Int J Oncol1995;6:333-43

[26] Sobel RE,Sadar MD.Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells..In Vitro Cell Dev Biol Anim2006;42:33-9

[27] Centenera MM,Knudsen KE,Butler LM.Ex vivo culture of human prostate tissue and drug development..Nat Rev Urol2013;10:483-7

[28] Fox EJ,Emond MJ.Accuracy of next generation sequencing platforms..Next Gener Seq Appl2014;1:pii: 1000106

[29] Gawad C,Quake SR.Single-cell genome sequencing: current state of the science..Nat Rev Genet2016;17:175-88